| First Author | Zhao X | Year | 2022 |
| Journal | Int J Mol Sci | Volume | 23 |
| Issue | 2 | PubMed ID | 35054815 |
| Mgi Jnum | J:322474 | Mgi Id | MGI:6861285 |
| Doi | 10.3390/ijms23020629 | Citation | Zhao X, et al. (2022) Analysis of the Biomarkers for Neurodegenerative Diseases in Aged Progranulin Deficient Mice. Int J Mol Sci 23(2) |
| abstractText | Neurodegenerative diseases are debilitating impairments that affect millions of people worldwide and are characterized by progressive degeneration of structure and function of the central or peripheral nervous system. Effective biomarkers for neurodegenerative diseases can be used to improve the diagnostic workup in the clinic as well as facilitate the development of effective disease-modifying therapies. Progranulin (PGRN) has been reported to be involved in various neurodegenerative disorders. Hence, in the current study we systematically compared the inflammation and accumulation of typical neurodegenerative disease markers in the brain tissue between PGRN knockout (PGRN KO) and wildtype (WT) mice. We found that PGRN deficiency led to significant neuron loss as well as activation of microglia and astrocytes in aged mice. Several characteristic neurodegenerative markers, including alpha-synuclein, TAR DNA-binding protein 43 (TDP-43), Tau, and beta-amyloid, were all accumulated in the brain of PGRN-deficient mice as compared to WT mice. Moreover, higher aggregation of lipofuscin was observed in the brain tissue of PGRN-deficient mice compared with WT mice. In addition, the autophagy was also defective in the brain of PGRN-deficient mice, indicated by the abnormal expression level of autophagy marker LC3-II. Collectively, comprehensive assays support the idea that PGRN plays an important role during the development of neurodegenerative disease, indicating that PGRN might be a useful biomarker for neurodegenerative diseases in clinical settings. |
